(Medscape Medical News) Aug 22, 2017 - Azacitidine (Vidaza, Celgene) is standard treatment for patients with myelodysplastic syndrome (MDS) and will remain the treatment of choice — at least for now.

(Yahoo! Finance) Aug 21, 2017 - Syros Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia (AML).